Targeting inflammation in cardiovascular risk
The adverse effects of low-grade systemic inflammation are associated with the development of atherosclerosis, heart failure, obesity-related metabolic disorders, and chronic kidney disease. Because inflammation drives residual cardiovascular risk, Cardiometabolic Health Congress (CMHC) explores current and emerging anti-inflammatory agents in this setting. Inflammation in Atherosclerosis Atherosclerosis is no longer thought to be simply the result […]
Inflammation and risk of T2DM: Insights from the CANTOS trial
Data from several studies have suggested that persistent low-grade inflammation has an important role in the pathophysiology of many cardiometabolic conditions. Inflammatory markers, such as interleukin-6 (IL-6) and high-sensitivity C-reactive protein (hs-CRP) have been associated with increased risk of cardiovascular adverse events, as well as insulin resistance and hyperglycemia. Canakinumab is a human monoclonal antibody […]
